Trial Profile
A Phase III Double-Blind Randomized Crossover Study of Plerixafor Versus G-CSF in the Treatment of Patients With WHIM Syndrome
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 20 Oct 2023
Price :
$35
*
At a glance
- Drugs Plerixafor (Primary) ; Granulocyte colony-stimulating factors
- Indications WHIM syndrome
- Focus Adverse reactions
- 02 Oct 2023 Primary endpoint has not been met, (Severity of Infection), as per Results published in the Journal of Clinical Investigation
- 02 Oct 2023 Results published in the Journal of Clinical Investigation
- 25 Feb 2021 Status changed from active, no longer recruiting to completed.